Quantbot Technologies LP purchased a new position in Amedisys, Inc. (NASDAQ:AMED – Free Report) in the first quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 8,260 shares of the health services provider’s stock, valued at approximately $761,000.
Other institutional investors also recently made changes to their positions in the company. Banque Cantonale Vaudoise acquired a new stake in shares of Amedisys in the 1st quarter worth approximately $60,000. Cetera Trust Company N.A bought a new stake in shares of Amedisys in the 4th quarter worth approximately $215,000. CWM LLC raised its holdings in shares of Amedisys by 40.4% in the 4th quarter. CWM LLC now owns 2,629 shares of the health services provider’s stock worth $250,000 after purchasing an additional 757 shares in the last quarter. Contravisory Investment Management Inc. bought a new stake in shares of Amedisys in the 4th quarter worth approximately $258,000. Finally, Mesirow Institutional Investment Management Inc. raised its holdings in shares of Amedisys by 9.9% in the 4th quarter. Mesirow Institutional Investment Management Inc. now owns 2,844 shares of the health services provider’s stock worth $270,000 after purchasing an additional 257 shares in the last quarter. 94.36% of the stock is owned by institutional investors and hedge funds.
Amedisys Stock Performance
AMED stock opened at $98.09 on Monday. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $3.21 billion, a price-to-earnings ratio of -153.26, a P/E/G ratio of 2.40 and a beta of 0.79. Amedisys, Inc. has a 12 month low of $89.55 and a 12 month high of $98.46. The firm has a 50 day moving average of $94.23 and a two-hundred day moving average of $93.58.
Wall Street Analyst Weigh In
A number of analysts recently commented on AMED shares. Cantor Fitzgerald reiterated a “neutral” rating and issued a $101.00 target price on shares of Amedisys in a report on Thursday, April 25th. Raymond James reiterated a “market perform” rating on shares of Amedisys in a report on Tuesday, March 26th. Royal Bank of Canada boosted their target price on shares of Amedisys from $97.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 25th. William Blair downgraded shares of Amedisys from an “outperform” rating to a “market perform” rating in a report on Monday, July 1st. Finally, StockNews.com upgraded shares of Amedisys from a “hold” rating to a “buy” rating in a report on Saturday, May 4th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $100.67.
Read Our Latest Analysis on Amedisys
Amedisys Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
See Also
- Five stocks we like better than Amedisys
- Overbought Stocks Explained: Should You Trade Them?
- Positive News is Driving This Cancer Drug Maker’s Stock Higher
- Basic Materials Stocks Investing
- Top 3 Defense Stocks That Should Be on Your Radar
- Insider Buying Explained: What Investors Need to Know
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.